Last reviewed · How we verify
CU06-1004, Multiple doses
At a glance
| Generic name | CU06-1004, Multiple doses |
|---|---|
| Also known as | SAC-1004, CU06, CU06-RE |
| Sponsor | Curacle Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of CU06-1004 in Patients With Daibetic Macular Edema (PHASE2)
- First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CU06-1004, Multiple doses CI brief — competitive landscape report
- CU06-1004, Multiple doses updates RSS · CI watch RSS
- Curacle Co., Ltd. portfolio CI